Brands and Their Owners
Welcome to the Brand page for “HB”, which is offered here for The mark consists of the letters hb in lower case letters with the letter h at the top and the letter b on the bottom sharing the end of the letter h slant to form the b inside of a slanted shaded square.;intravenous solution for use in the treatment of viral infections, immune disorders, cancer and me/cfs; intravenous solution for use in the treatment of injuries resulting from surgery, thermal accidents or burns; interferons; parenterally administered interferon for use in treating viral diseases, immunological disorders and cancer; pharmaceutical products, pharmaceutical preparations for treatment of viral and infectious diseases, cancer, immune disorders and me/cfs;color is not claimed as a feature of the mark.;pharmaceutical research and development; pharmaceutical research and development of drugs for the treatment of cancers, viral diseases, immunological disorders and me/cfs;.
Its status is currently believed to be active. Its class is unavailable. “HB” is believed to be currently owned by “AIM IMMUNOTECH INC.”
Owner: |
AIM IMMUNOTECH INC.
Owner Details |
---|---|
Description: |
The mark consists of the letters hb in lower case letters with the letter h at the top and the letter b on the bottom sharing the end of the letter h slant to form the b inside of a slanted shaded square.;Intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of injuries resulting from surgery, thermal accidents or burns; Interferons; Parenterally administered interferon for use in treating viral diseases, immunological disorders and cancer; Pharmaceutical products, pharmaceutical preparations for treatment of viral and infectious diseases, cancer, immune disorders and ME/CFS;Color is not claimed as a feature of the mark.;Pharmaceutical research and development; Pharmaceutical research and development of drugs for the treatment of cancers, viral diseases, immunological disorders and ME/CFS;
|
Categories: |